A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: Background and methodology of the MONITOR-CKD5 study

Internal and Emergency Medicine

Volumn 8, Issue 5, 2013, Pages 389-399

  Gesualdo, Loreto ^a   London, Gérard ^b   Turner, Matthew ^c   Lee, Christopher ^d,e   MacDonald, Karen ^d   Goldsmith, David ^f   Covic, Adrian ^g   Zaoui, Philippe ^h   Combe, Christian ⁱ   Mann, Johannes ^j   Dellanna, Frank ^k   Muenzberg, Michael ^c   Abraham, Ivo ^d,e  

^a UNIVERSITY OF BARI   (Italy)

^b Centre Hospitalier F H Manhès   (France)

^c Sandoz Pharma Ltd   (Switzerland)

^d Matrix45 ^*  (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁱ INSERM   (France)

^j UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^k Dialysezentrum   (Germany)

more..

Author keywords

Biosimilar; Erythropoietin; Haemodialysis; Pharmacoepidemiology; Renal anaemia

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PHARMACOEPIDEMIOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADULT; ANEMIA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PHARMACOEPIDEMIOLOGY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84880421358     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0622-7     Document Type: Article

References (32)

1. McClellan WM, Jurkovitz C, Abramson J (2005) The epidemiology and control of anemia among pre-ESRD patients with chronic kidney disease. Eur J Clin Invest 35(Suppl 3): 58-65.
2. Eckardt KU (2000) Pathophysiology of renal anemia. Clin Nephrol 53(Suppl): S2-S8.
3. (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (Suppl 1): S1-266.
4. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J (2002) Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 162: 1401-1408.
5. Locatelli F, Pisoni RL, Combe C et al (2004) Anemia in hemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 121-132.
6. Rao M, Pereira BJ (2005) Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int 68: 1432-1438.
7. (2007) K/DOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of haemoglobin target. Am J Kidney Dis 50: 471-530.
8. Locatelli F, Aljama P, Barany P et al (2004) Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 19(Suppl 2): ii1-ii47.
9. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R (2009) Anemia management in patients with chronic kidney disease: a position statement by the Anemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 24: 348-354.
10. Jacobs C, Hörl WH, Macdougall IC et al (2000) European Best Practice Guidelines 5: target haemoglobin. Nephrol Dial Transplant 15(Suppl 4): 15-19.
11. Jacobs C, Frei D, Perkins AC (2005) Results of the European Survey on Anemia Management 2003 (ESAM 2003): current status of anemia management in dialysis patients, factors affecting epoetin dosage and changes in anemia management over the last 5 years. Nephrol Dial Transplant 20(Suppl 3): iii3-iii24.
12. Pisoni RL, Bragg-Gresham JL, Young EW et al (2004) Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44: 94-111.
13. Hörl WH, Vanrenterghem Y, Canaud B et al (2005) Optimal treatment of renal anemia (OPTA): improving the efficacy and efficiency of renal anemia therapy in hemodialysis patients receiving intravenous epoetin. Nephrol Dial Transplant 20(Suppl 3): iii25-iii32.
14. Port FK, Pisoni RL, Bommer J et al (2006) Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 1: 246-255.
15. Port FK, Pisoni RL, Bragg-Gresham JL et al (2004) DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 22: 175-180.
16. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ (2008) Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 3: 133-138.
17. Kimata N, Akiba T, Pisoni RL et al (2005) Mineral metabolism and hemoglobin concentration among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 20: 927-935.
18. Rayner HC, Pisoni RL, Bommer J et al (2004) Mortality and hospitalization in hemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 108-120.
19. Volkova N, Arab L (2006) Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 47: 24-36.
20. Holden JE, Kelley K, Agarwal R (2008) Analyzing change: a primer on multilevel models with applications to nephrology. Am J Nephrol 28: 792-801.
21. Strippoli GF, Navaneethan SD, Craig JC (2006) Hemoglobin and hematocrit targets for the anemia of chronic kidney disease. Cochrane Database Syst Rev 4: CD003967.
22. Locatelli F, Nissenson AR, Barrett BJ et al (2008) Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 74: 1237-1240.
23. Pfeffer M, Burdmann EA, Cooper DE et al (2009) A trial of darbepoetin-alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 1-14.
24. Singh AK (2009) Does TREAT give the boot to ESAs in the treatment of CKD anemia. J Am Soc Nephrol 21: 2-6.
25. Goldsmith D, Covic A (2010) Time to reconsider evidence for anaemia treatment (TREAT) = essential safety arguments (ESA). Nephrol Dial Transplant 25: 1734-1737.
26. Timmermans S, Mauck A (2005) The promises and pitfalls of evidence-based medicine. Health Aff 24: 18-28.
27. Sörgel F, Thyroff-Friesinger U, Vetter A et al (2009) Bioequivalence of HX575 (IV) (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol 9: 10.
28. Sörgel F, Thyroff-Friesinger U, Vetter A et al (2009) Bioequivalence of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. Int J Clin Pharmacol Ther 6: 391-401.
29. Brockmeyer C, Seidl A (2009) Binocrit: assessment of quality, safety, and efficacy of biopharmaceuticals. Eur J Hosp Pharm Pract 15: 34-40.
30. Haag-Weber M, Vetter A, Thyroff-Friesinger U et al (2009) Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 72: 380-390.
31. Geller NL, Pocock SJ (1987) Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics 43: 213-223.
32. Schulz KF, Grimes DA (2005) Multiplicity in randomised trials II: subgroup and interim analyses. Lancet 365: 1657-1661.